ired in
most 510(k) applications; however if clinical data are necessary to demonstrate
substantial equivalence, the clinical studies need to be conducted in compliance withthe
requirements of the IDE regulations, IRB review and informed consent (21 CFR parts 812, 56
and 50, respectively). </p>

<p><b>3. Why should an IRB decide whether a device is non-significant risk (NSR)? 
  </b></p>

<p>The sponsors (usually the manufacturer of the device) makes the initial decision
whether a device imparts s